Clay Siegall Uses His Blog To Share Stories About Science And Football

Clay Siegall’s blog is filled with news stories about things he finds interesting the fields of science and sports. One recent science article he posted came from PBS and was about the flu epidemic that has been striking people across the United States in recent months. The article was about the Gesundheit Machine located at the University of Michigan. He enrolls students sick with the flu to sit in the Gesundheit Machine so that research can be performed on how the flu spreads from person to person.

In another article Clay Siegall posted it was about the surprise trade of Alex Smith, going from the Chiefs to the Redskins. The current quarterback of the Redskins, Kirk Cousins, said he hadn’t known anything about his team’s interest in trading for Alex Smith before the trade occurred. This Offseason Kirk Cousins is a free agent and it is likely he’ll now sign with another team instead of going back to the Redskins.

As one of the co-founders of Seattle Genetics, Clay Siegall is now the top executive at this company headquartered in Bothell, Washington. He is the president, CEO, and chairman. He was trained as a scientist and has focused his entire career on curing cancer. He and his team research targeted cancer drugs which he thinks is the way that all cancer will be treated in the future.

As the top executive, Clay Siegall has entered into many strategic licenses with other companies in the biotechnology industry. These licenses both help his company’s research and their ability to get drugs on the market. His licenses for his ADC technology has generated over $300 million in revenue for his company. He has signed these licenses with companies like Pfizer, Roche, and Abbvie.

Seattle Genetics under Clay Siegall’s leadership has grown by leaps and bounds into becoming one of the top cancer drug companies in the United States. Seattle Genetics now has 12 drugs in development and they started hiring 100 more people in 2017. Clay Siegall also bought another company in the industry, Cascadian Therapeutics, in a deal for $614 billion that was finalized on January 31, 2018.